Newsletters
FDA Continues to Create More Communication Pathways Between Payors and Companies
September 2018
Rowinski Group considers the Federal Food and Drug Administration‘s (FDA) efforts to facilitate communication pathways between medical technology companies and payors relevant because the pathways may offer companies opportunities to begin reimbursement planning for their medical or digital technology well before it is cleared or approved by the FDA.
Reimbursement Summit for Medical Device & Digital Health Companies
August 2018
Reimbursement summits dedicated exclusively to medical devices and digital health technologies are not held often, so we wanted to make you aware of this summit to be held in October.
Medicare Proposes to Cut Hospital Reimbursement Amounts
May 2018
We are sending this brief to bring to your attention the importance of monitoring healthcare payers’ decisions and the creation of new payer policies, both events could impact your company’s income and business objectives. Keeping abreast of healthcare payer changes could be a worthwhile.
Consolidation of Medicare Contractors and Company Revenues
January 2018
Change to a new contractor could impact how future local Medicare coverage decisions and other policy matters are made in California and nation and could have repercussions on companies’ sales and commercialization efforts.
Preliminary Changes to Medicare Reimbursement for Clinicians
December 2016
We believe Medicare’s Quality Payment Program may offer unique opportunities to monetize your medical device, diagnostic test or digital health technology outside of traditional reimbursement pathways. It takes time to determine the value of incorporating the Quality Payment Program into your product development, clinical trial, and sales efforts.
Physician Reimbursement Reforms and New Delivery Models under Medicare
May 2015
We are sending this brief to provide you with practical ideas on how to use reimbursement data and payer decisions and policy to help you adjust your business plans and objectives. We consider payer policy and data to be a source of high-quality market intelligence because it is timely, actual (not forecasted) and derived from reputable sources.
Medical Mobile Apps Reimbursement and the American Medical Association (AMA)
June 2014
We are sending this brief as way to provide you with practical ideas on how to use reimbursement policy and data to help you adjust and define your business plans and objectives.
FDA and CMS Concurrent Review Pilot Program for Medical Devices
June 2014
We are sending this brief as way to provide you with practical ideas on how to use reimbursement policy and data to help you adjust and define your business plans and objectives.